A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

14012

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Prevention of Atherosclerotic Cardiovascular Disease

Interventions

DRUG: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
DRUG: Placebo in 1.5ml

Sponsor

Novartis Pharmaceuticals